Trial Profile
A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 04 Jan 2024
Price :
$35
*
At a glance
- Drugs Leronlimab (Primary)
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
- Sponsors CytoDyn
- 13 Jan 2022 Planned End Date changed from 15 Oct 2021 to 15 Jun 2022.
- 09 Dec 2021 Results presented in a CytoDyn Media Release.
- 08 Dec 2021 Results of subgroup analysis from this trial published in the CytoDyn Media Release